Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 491-500

  Seitz, Guido ^a   Bonin, Michael ^a   Fuchs, Jörg ^a   Poths, Sven ^a   Ruck, Peter ^b   Warmann, Steven W ^a   Armeanu Ebinger, Sorin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

Glutathione S transferase; Multidrug resistance; Rhabdomyosarcoma

Indexed keywords

4 PHENYL 1,3,2 OXATHIAZOLYLIUM 5 OLEIC ACID; DOXORUBICIN; E 4754; ETACRYNIC ACID; GLUTATHIONE TRANSFERASE; ISOENZYME; OLEIC ACID; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUTATHIONE TRANSFERASE; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TOPOTECAN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75449102372     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000523     Document Type: Article

References (29)

1. Fuchs J, Wenderoth M, von Schweinitz D, Haindl J and Leuschner I: Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplantated hepatoblastoma. Cancer 83: 2400-2407, 1998.
2. Cocker HA, Pinkterton CR and Kelland LR: Characterization and modulation of drug resistance of human rhabdomyosarcoma cell lines. Br J Cancer 83: 338-345, 2000.
3. Crist WM, Anderson JR, Meza JL, et al: Intergroup rhabdomyosarcoma study-IV: results of patients with non-metastatic disease. J Clin Oncol 19: 3091-3102, 2001.
4. Newton WA Jr, Gehan EA, Webber BL, et al: Classification of rhabdomyosarcomas and related sarcomas. Cancer 76: 1073-1085, 1995.
5. Lawrence W Jr, Anderson JR, Gehan EA and Maurer H: Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup study group. Children's cancer study group. Pediatric Oncology Group. Cancer 80: 1165-1170, 1997.
6. Treuner J and Koscielniak E: Cooperative Weichteilsarkom - Studie CWS 2002-P. Study protocol, 2003.
7. Stevens MC, Rey A, Bouvet N, et al: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the international society of paediatric oncology - SIOP malignant mesenchymal tumor 89. J Clin Oncol 23: 2586-2587, 2005.
8. Meza JL, Anderson J, Pappo AS, Meyer WH and Children's Oncology Group: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the children's oncology group. J Clin Oncol 24: 3844-3851, 2006.
9. Ferrari A, Casanova M, Bisogno G, et al: Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer 97: 2597-2604, 2003.
10. Seitz G, Warmann SW, Vokuhl CO, et al: Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int 23: 431-439, 2007.
11. Townsend DM and Tew KD: The role of glutathione-Stransferase in anti-cancer drug resistance. Oncogene 22: 7369-7375, 2003.
12. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320, 1994.
13. Depeille P, Cuq P, Mary S, Passagne I, Evrard A, Cupissol D and Vian L: Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 65: 897-905, 2004.
14. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625, 1988.
15. Wu Z, Irizarry RA, Gentleman R, Murillo FM and Spencer F: A model based background adjustment for oligonucleotide expression arrays. Department of Biostatics Working Papers, John Hopkins University, Baltimore, MD, 2003.
16. Benjamini Y and Hochberg Y: Controlling the False Discovery Rate: a practical and powerful approach to multiple testing: Journal of the Royal Statistical Society B 57: 289-300, 1995.
17. Singer D, Demetri GD, Baldini EH and Fletcher CD: Management of soft-tissue sarcoma: an overview and update. Lancet Oncol 1: 75-85, 2000.
18. Cowie FJ, Pinkterton CR, Phillips M, Dick M, Judson I, McCarthy PT and Flanagan RJ: Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877-881, 1995.
19. Kotchetkov R, Cinatl J, Blaheta R, et al: Development of resistance to vincristine and doxorubicine in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36-43, 2003.
20. Su F, Hu X, Jia W, Gong C, Song E and Hamar P: Gluthation S Transferase π indicates chemotherapy resistance in breast cancer. J Surg Res 113: 102-108, 2003.
21. McIlwain CC, Townsend DM and Tew KD: Glutathione Stransferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648, 2006.
22. Mayr D, Pannekamp U, Baretton GB, et al: Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Prac 196: 469, 2000.
23. Shiga H, Heath EI, Rasmussen AA, et al: Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5: 4097-4104, 1999.
24. Inoue T, Ishida T, Sugio K, Maehara Y and Sugimachi K: Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 62: 223-227, 1995.
25. Cui H, Shen J, Lu D, Zhang T, Zhang W, Sun D and Wang PG: 4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy. Cancer Chemother Pharmacol 62: 509-515, 2008.
26. Ploemen JH, Van Schanke A, Van Ommen B and Van Bladeren PJ: Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P1-1. Cancer Res 54: 915-919, 1994.
27. Rosario LA, O'Brien ML, Henderson CJ, Wolf CR and Tew KD: Cellular response to a gluthatione S-transferase P1-1 activated prodrug. Mol Pharmacol 58: 167-174, 2000.
28. Tew KD: TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14: 1047-1054, 2005.
29. Castro B, Alonso-Varona A, del Olmo M, Bilbao P and Palomares T: Role of gamma-glutamyltranspeptidase on the reponse of poorly and moderately differentiated rhabdomyosarcoma cell lines to buthionine sulfoximine-induced inhibition of glutathione synthesis. Anticancer Drugs 13: 281-291, 2002.